Rate Limiting Steps of AAV Transduction and Implications for Human Gene Therapy
The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
Despite the fact that adeno-associated virus type 2 (AAV2) is an extremely attractive gene therapy vector, its application has been limited to certain tissues such as muscle and the brain. In an attempt to broaden the array of target organs for this vector, molecular studies on the mechanism(s) of AAV transduction have expanded over the past several years. These studies have led to the development of innovative strategies capable of overcoming intracellular barriers to AAV2 transduction. The basis of these technologic breakthroughs has stemmed from a better understanding of the molecular processes that control AAV entry and intracellular trafficking to the nucleus. This review will focus on the identification of molecular components important for recombinant AAV (rAAV) transduction while highlighting the techniques used to discover them and potential clinical application of research findings.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ferrari, F. K., Samulski, T., Shenk, T., & Samulski, R. J. (1996) · Journal of Virology · doi:10.1128/jvi.70.5.3227-3234.1996 · Cited by 761 · cited 2×
“Conversion from the single stranded DNA (ssDNA) to duplex form has been introduced as one of the most important rate limiting steps in AAV transduction (Ferrari et al., 1996; Fisher et al., 1996a).”
BackgroundImmune responses to adenovirus and adeno-associated virus in humans
Chirmule, N., Propert, K. J., Magosin, S. A., Qian, Y., Qian, R., & Wilson, J. M. (1999) · Gene Therapy · doi:10.1038/sj.gt.3300994 · Cited by 684 · cited 1×
“Considering the fact that HSV (Brehm et al., 1999) and adeno-viruses (Chirmule et al., 1999) generate an immune response in vivo, administration of such hybrid viruses for gene therapy might be most advantageous in diseases such as cancer (Dachs et al., 1997).”
BackgroundFab1p PtdIns(3)P 5-Kinase Function Essential for Protein Sorting in the Multivesicular Body
Odorizzi, G., Babst, M., & Emr, S. D. (1998) · Cell · doi:10.1016/s0092-8674(00)81707-9 · Cited by 656 · cited 1×
“These messengers are known to regulate vesicular trafficking (Odorizzi et al., 1998) and the rearrangement of cytoskeletal proteins such as actin (Kapeller and Cantley, 1994).”
BackgroundRecombinant adeno-associated virus for muscle directed gene therapy
Fisher, K. J., Jooss, K., Alston, J., Yang, Y., Haecker, S. E., High, K., Pathak, R., Raper, S. E., & Wilson, J. M. (1997) · Nature Medicine · doi:10.1038/nm0397-306 · Cited by 654
Gene therapy vectors based on adeno-associated virus type 1
Xiao, W., Chirmule, N., Berta, S. C., McCullough, B., Gao, G., & Wilson, J. M. (1999) · Journal of Virology · doi:10.1128/jvi.73.5.3994-4003.1999 · Cited by 541 · cited 1×
“In addition, existence of at least six different AAV serotypes (AAV1 to 6) has been reported (Halbert et al., 2000; Rutledge et al., 1998; Xiao et al., 1999).”
BackgroundInfectious entry pathway of adeno-associated virus and adeno-associated virus vectors
Bartlett, J. S., Wilcher, R., & Samulski, R. J. (2000) · Journal of Virology · doi:10.1128/jvi.74.6.2777-2785.2000 · Cited by 532 · cited 8×
“K44Adynamin) significantly reduced the endocytosis of rAAV virus (Bartlett et al., 2000; Duan et al., 1999).”
BackgroundResultInfluentialDavidson, B. L., Stein, C. S., Heth, J. A., Martins, I., Kotin, R. M., Derksen, T. A., Zabner, J., Ghodsi, A., & Chiorini, J. A. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.7.3428 · Cited by 531
Duan, D., Sharma, P., Yang, J., Yue, Y., Dudus, L., Zhang, Y., Fisher, K. J., & Engelhardt, J. F. (1998) · Journal of Virology · doi:10.1128/jvi.72.11.8568-8577.1998 · Cited by 522 · cited 3×
“In fact, strong evidence exists that rAAV is mostly retained as large episomal circular concatamers in muscle (Duan et al., 1998a; Yang et al., 1999), while studies in liver suggest that these large circular concatamers may integrate into host chromosomes at a higher efficiency (Ponnazhagan et al.,…”
BackgroundSelf-citationGenetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2
Girod, A., Ried, M., Wobus, C., Lahm, H., Leike, K., Kleinschmidt, J., Deléage, G., & Hallek, M. (1999) · Nature Medicine · doi:10.1038/12491 · Cited by 405
Endosomal processing limits gene transfer to polarized airway epithelia by adeno-associated virus
Duan, D., Yue, Y., Yan, Z., Yang, J., & Engelhardt, J. F. (2000) · Journal of Clinical Investigation · doi:10.1172/jci8317 · Cited by 391 · cited 3×
“Using this same strategy, a dual vector approach was also exploited to augment rAAV mediated gene expression by co-infection with an enhancer carrying vector and promoters or minimal promoter transgene expre-ssing vector (Duan et al., 2000a).”
BackgroundMethodSelf-citation
Cited by
Burger, C., Gorbatyuk, O. S., Velardo, M. J., Peden, C. S., Williams, P., Zolotukhin, S., Reier, P. J., Mandel, R. J., & Muzyczka, N. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2004.05.024 · Cited by 741
GENE THERAPY: Twenty-First Century Medicine
Verma, I. M., & Weitzman, M. D. (2005) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.74.050304.091637 · Cited by 616
Gao, K., Li, M., Zhong, L., Su, Q., Li, J., Li, S., He, R., Zhang, Y., Hendricks, G., Wang, J., et al. (2014) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2013.9 · Cited by 165
The Mre11/Rad50/Nbs1 complex limits adeno-associated virus transduction and replication
Schwartz, R. A., Palacios, J. A., Cassell, G. D., Adam, S., Giacca, M., & Weitzman, M. D. (2007) · Journal of Virology · doi:10.1128/jvi.01523-07 · Cited by 130
Gene targeting with viral vectors
Hendrie, P. C., & Russell, D. W. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.04.006 · Cited by 126
“The precise mechanism by which vector virions are uncoated is not known, and this may be a rate-limiting step in transduction resulting in a slow release of vector DNA into the nucleus [46,47].”
Background
Metadata
- Authors
- Sanlioglu, S., Monick, M., Luleci, G., Hunninghake, G., & Engelhardt, J.
- Venue
- Current Gene Therapy
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2001-07-01
- Volume
- 1
- Issue
- 2
- Pages
- 137-147
- ISSN
- 1566-5232 (ISSN-L)
- OpenAlex
- W2114904588
- Cited by
- 85
- References
- 21
- FWCI
- 1.73
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Rate Limiting Steps of AAV Transduction and Implications for Human Gene Therapy. https://app.cochat.ai/papers/10.2174/1566523013348788
- The paper
- Sanlioglu, S., Monick, M., Luleci, G., Hunninghake, G., & Engelhardt, J. (2001). Rate Limiting Steps of AAV Transduction and Implications for Human Gene Therapy. Current Gene Therapy. https://doi.org/10.2174/1566523013348788
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.